The Primary Hyperoxaluria drugs in development market research report provides comprehensive information on the therapeutics under development for Primary Hyperoxaluria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Primary Hyperoxaluria. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Primary Hyperoxaluria and features dormant and discontinued products.
GlobalData tracks 12 drugs in development for Primary Hyperoxaluria by 11 companies/universities/institutes. The top development phase for Primary Hyperoxaluria is discovery with four drugs in that stage. The Primary Hyperoxaluria pipeline has 12 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Primary Hyperoxaluria pipeline products market are: Intellia Therapeutics, Arbor Biotechnologies and Cantero Therapeutics.
The key targets in the Primary Hyperoxaluria pipeline products market include Hydroxyacid Oxidase 1 (Glycolate Oxidase or HAO1 or EC 1.1.3.15), L-Lactate Dehydrogenase A Chain (Cell Proliferation Inducing Gene 19 Protein or LDH Muscle Subunit or Renal Carcinoma Antigen NY REN 59 or LDHA or EC 1.1.1.27), and Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3).
The key mechanisms of action in the Primary Hyperoxaluria pipeline product include Hydroxyacid Oxidase 1 (Glycolate Oxidase or HAO1 or EC 1.1.3.15) Inhibitor with three drugs in Phase II. The Primary Hyperoxaluria pipeline products include two routes of administration with the top ROA being Oral and four key molecule types in the Primary Hyperoxaluria pipeline products market including Gene Therapy, and Small Molecule.
Primary Hyperoxaluria overview
Primary hyperoxaluria is a rare condition characterized by recurrent kidney and bladder stones. It results from the overproduction of a substance called oxalate. Symptoms include blood in the urine, pain when urinating, fever, sudden abdominal pain, and frequent urge to urinate. Treatment includes oral preparations of phosphates and diuretics.
For a complete picture of Primary Hyperoxaluria’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
